Polymer-Cisplatin Conjugate Nanoparticles for Acid-Responsive Drug Delivery

Department of Nanoengineering and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, USA.
ACS Nano (Impact Factor: 12.88). 01/2010; 4(1):251-8. DOI: 10.1021/nn9014032
Source: PubMed


We report the synthesis of novel acid-responsive therapeutic nanoparticles (NPs) with sub-100 nm size consisting of polymer--cisplatin conjugates. The uniqueness of these drug delivery polymeric NPs lies in the covalent conjugation of each cisplatin drug to the hydrophobic segment of two biocompatible diblock copolymer chains through a hydrazone bond, resulting in highly differential drug release profile at different environmental acidity. We demonstrate that the synthesized polymer--cisplatin conjugates can readily precipitate to form sub-100 nm NPs in aqueous solution due to their very low critical micelle concentration (CMC). The resulting NPs show well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells as compared to free cisplatin. As an environmentally sensitive drug delivery vehicle, these NPs can potentially minimize the drug loss during NP circulation in the blood, where the pH value is neutral, and trigger rapid intracellular drug release after the NPs are endocytosed by the target cells. This characteristic drug release profile holds the promise to suppress cancer cell chemoresistance by rapidly releasing a high dose of chemotherapy drugs inside the tumor cells, thereby improving the therapeutic efficacy of the drug payload.

Download full-text


Available from: Che-Ming Jack Hu
  • Source
    • "Data are expressed as mean ± SDs (n = 4). prodrug conjugates prepared by coupling drugs to the hydrophobic segments of amphiphilic copolymers could improve the drug solubility and stability [58] [59] [60], these nanoparticulate systems often showed a delayed drug release behavior. The underlying reason is that drugs were still encapsulated in micelles or nanoparticles after drugs cleaved from the polymer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Self-assembled prodrug nanoparticles have demonstrated great promise in cancer chemotherapy. In the present study, we developed a new kind of prodrug nanoparticles for targeted drug delivery. PEGylated doxorubicin conjugate with an acid-cleavable cis-aconityl spacer was prepared. Then it was functionalized with a tumor-penetrating peptide, Cys-Arg-Gly-Asp-Lys (CRGDK), providing the prodrug nanoparticles with the specific binding ability to neurophilin-1 receptor. In acid mediums, doxorubicin could be released from the prodrug nanoparticles with an accumulative release around 60% through the acid-triggered hydrolysis of cis-aconityl bond and nanoparticle disassembly. Whereas, drug release was slow under a neutral pH and the accumulative drug release was less than 16%. In the cell culture tests, our prodrug nanoparticles showed enhanced endocytosis and cytotoxicity in cancer cells including HepG2, MCF-7 and MDA-MB-231 cells, but lower cytotoxicity in human cardiomyocyte H2C9. In the animal experiments, the prodrug nanoparticles were intravenously injected into Balb/c nude mice bearing MDA-MB-231 tumors. Enhanced drug penetration and accumulation in tumors, accompanying with a rapid early tumor-binding behavior, was observed after intravenous injection of the peptide modified prodrug nanoparticles. These data suggests that the acid-sensitive and tumor-targeting PEGylated doxorubicin prodrug nanoparticle may be an efficient drug delivery system for cancer chemotherapy.
    Full-text · Article · Oct 2015 · Colloids and surfaces B: Biointerfaces
  • Source
    • "Other drugs like vincristine, verapamil, cyclosporin, paclitaxel, oxaliplatin, cisplatin , and curcumin have been delivered using polymeric (NPs) and nanoemulsions made of surfactants (Soma et al., 2000; Devalapally et al., 2007; van Vlerken et al., 2007; Abu Lila et al., 2009; Ganta and Amiji, 2009; Song et al., 2009; Yadav et al., 2009; Aryal et al., 2010). This combinatorial delivery of multiple drugs and MDR inhibitors opens up a huge amount of schemes to target the comprehensive mechanisms of MDR especially via the EPR effect, and at the same time it lifts up some important concerns about this approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a major cause of mortality in the modern world, with more than 10 million new cases every year. This outline is expected to rise in the next few decades since the majority (59%) of people diagnosed with cancer is aged over 65. In fact, around one in three people will be diagnosed with cancer throughout their lifetime (Bosetti et al., 2013;Siegel et al., 2012). The foundation of cancer treatment is surgery, chemotherapy, radiation, antibody-blocking therapy, or a combination of these therapies (Hanahan and Weinberg, 2000). Still, many clinical chemotherapeutic and radiotherapeutic regimes are not exceptionally effective, due to multidrug resistance mechanisms, depending on the patient and the type of tumour. Therefore, there is an urgent need for more effective and valuable cancer therapeutics, in order to reduce the impact of the chemotherapeutic agents on the healthy tissues by creating more selective systems towards the cancerous cells (Perez-Tomas, 2006;Alison, 2001).
    Full-text · Article · Oct 2013 · Frontiers in Pharmacology
  • Source
    • "Compared to the neutral pH in most human tissues, acidic environments are found within the cell in endosomes or lysosomes [21e23] or in tumor microenvironments [24] [25]. Different pHresponsive chemical bonds, such as acetal [26e28], orthoester [29] [30], hydrazone [31], imine [32], vinylether [33] [34], maleic acid amide [35e39], and b-thiopropionate [40] [41] were employed in the design of stimuli-responsive drug delivery systems. However, the number of successfully developed acid-responsive drug carriers is still limited. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stimuli-responsive drug carriers have great potential to deliver bioactive materials on demand and to a specific location within the human body. Acid-responsive drug carriers can specifically release their payload in the acidic microenvironments of tumors or in the endosomal or lysosomal compartments within a cell. Here we describe an approach to functionalize vicinal diols of dextran with hydrophobic boronate esters in order to produce a water insoluble boronate dextran polymer (B-Dex), which spontaneously forms acid-responsive nanoparticles in water. We show the encapsulation of a hydrophobic anticancer drug doxorubicin into the particles. Hydrolysis of the boronate esters under mild acidic conditions recovers the hydrophilic hydroxyl groups of the dextran and disrupts the particles into water soluble fragments thereby leading to a pH-responsive release of the drug. According to dynamic light scattering (DLS) and UV/Vis spectroscopy, mild acidic conditions (pH 5.0) lead to a three-fold increase in the degradation of the particles and a four-fold increase in the release of the drug compared to the behavior of particles at pH 7.4. In vitro tests in Hela cells show no toxicity of the empty B-Dex nanoparticles, while the toxicity of doxorubicin-loaded B-Dex nanoparticles is comparable to that of the doxorubicin·HCl drug. Confocal fluorescence microscopy reveals that 100% of the Hela cells uptake doxorubicin-loaded B-Dex nanoparticles with a preferential accumulation of the nanoparticles in the cytoplasm.
    Full-text · Article · Aug 2013 · Biomaterials
Show more